NovaBridge Biosciences Operating Lease, Right-of-Use Asset, Amortization Expense
NovaBridge Biosciences (NBP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of CNY 25.81 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-04-30
CNY
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|
| 2023-12-31 | 25.81M CNY 20-F · filed 2024-04-30 |
| 2022-12-31 | 34.52M CNY 20-F · filed 2024-04-30 |
| 2021-12-31 | 17.00M CNY 20-F · filed 2024-04-30 |
| 2020-12-31 | 8.16M CNY 20-F · filed 2023-05-01 |
USD
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|
| 2023-12-31 | $3.64M 20-F · filed 2024-04-30 |
| 2022-12-31 | $5.00M 20-F · filed 2023-05-01 |